Roivant CEO Matt Gline at #BIO24 (Brian Benton Photography)
Roivant says long-shot drug for a rare lung disease failed its Phase 2 study
Roivant reported a Phase 2 failure on Tuesday for a program analysts expected would not succeed.
The compound in question, namilumab, was being tested in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
